Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in
heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching
target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration
regimens.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination